In addition, there was no significant difference in the numbers of PD-1+, PD-1+ICOS+ and CD40L+ memory Tfh cells between the patients and HC as well as in MS patients before and after treatment (Data not shown). This evidence concerns the gene ICOS and myeloid sarcoma.